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ABSTRACT
Introduction: Dapagliflozin is a selective
inhibitor of the sodium–glucose co-transporter
2 (SGLT2) that increases urinary glucose
excretion to reduce hyperglycemia in the
treatment of type 2 diabetes mellitus. A robust
carcinogenicity risk assessment was undertaken
to assess the chronic safety of dapagliflozin and
SGLT2 inhibition.
Methods: Genotoxicity potential of
dapagliflozin and its metabolites was assessed
in silico, in vitro, and in vivo. Dapagliflozin was
administered daily by oral gavage to mice, rats,
and dogs to evaluate carcinogenicity risks,
including the potential for tumor promotion.
SGLT2-/- mice were observed to evaluate the
effects of chronic glucosuria. The effects of
dapagliflozin and increased glucose levels on a
panel of human bladder transitional cell
carcinoma (TCC) cell lines were also evaluated
in vitro and in an in vivo xenograft model.
Results: Dapagliflozin and its metabolites were
not genotoxic. In CD-1 mice and Sprague–
Dawley rats treated for up to 2 years at C1009
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human clinical exposures, dapagliflozin showed
no differences versus controls for tumor
incidence, time to onset for background
tumors, or urinary bladder proliferative/
preneoplastic lesions. No tumors or
preneoplastic lesions were observed in dogs
over 1 year at [3,0009 the clinical exposure of
dapagliflozin or in SGLT2-/- mice observed
over 15 months. Transcription profiling in
Zucker diabetic fatty rats showed that 5-week
dapagliflozin treatment did not induce tumor
promoter-associated or cell proliferation genes.
Increasing concentrations of glucose,
dapagliflozin, or its primary metabolite,
dapagliflozin 3-O-glucuronide, did not affect
in vitro TCC proliferation rates and
dapagliflozin did not enhance tumor growth
in nude mice heterotopically implanted with
human bladder TCC cell lines.
Conclusion: A multitude of assessments of
tumorigenicity risk consistently showed no
effects, suggesting that selective SGLT2
inhibition and, specifically, dapagliflozin are
predicted to not be associated with increased
cancer risk.
Keywords: Antidiabetic drug; Dapagliflozin;
Experimental pharmacology; Glycemic
control; SGLT2 inhibitor; Type 2 diabetes
mellitus
INTRODUCTION
Selective inhibitors of the sodium–glucose co-
transporter 2 (SGLT2) [1, 2] are a class of
antidiabetic agents with a novel mechanism of
action that can be additive and complementary
to existing antidiabetic therapies [3–5]. SGLT2
inhibitors promote urinary glucose excretion in
an insulin-independent manner to reduce
hyperglycemia and lower glycosylated
hemoglobin (HbA1c). Additional benefits
associated with SGLT2 inhibition include a
low risk of hypoglycemia, weight loss due to
urinary caloric loss [6], and diuresis-related
blood pressure lowering, with the potential for
cardiovascular benefits [7]. SGLT2 inhibition is
expected to be a relatively safe approach
because SGLT2 is selectively expressed in the
kidney [1, 8, 9]. Moreover, the limited data that
exist in subjects with familial renal glucosuria
due to mutations in the SGLT2 gene indicate
that this condition is largely asymptomatic
aside from increased glucosuria [10].
Nonetheless, drugs with novel mechanisms of
action require careful examination of potential
safety liabilities. In particular, elevated cancer
risk is an important concern for patients with
type 2 diabetes, since this patient population is
already at increased risk of a variety of tumor
types [11–13].
Dapagliflozin is a small-molecule inhibitor of
SGLT2 [3, 4] that has been shown to be highly
selective for SGLT2 compared with other SGLT
family members and to have no off-target
interactions in an in vitro screen of more than
330 receptors, enzymes, ion channels, and
transporters [14]. Overall, dapagliflozin
demonstrates good oral bioavailability, has a
high volume of distribution, and has an in vivo
metabolite profile that is qualitatively similar
between preclinical species and humans [15]. In
humans, the major circulating metabolite is a
stable, non-reactive ether glucuronide
[dapagliflozin 3-O-glucuronide (D3OG)] that
has no pharmacologic activity [15]. It also has
no structural alerts for mutagenicity or
carcinogenicity nor any off-target effects
against a similar broad panel of more than 330
receptors, enzymes, ion channels, and
transporters [14]. This glucuronide metabolite
is formed at a lower rate in preclinical species
but plasma concentrations comparable to or
higher than human exposures are achieved at
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supratherapeutic doses of dapagliflozin used for
toxicologic assessments [14]. Non-human
species also form a pharmacologically active
O-deethylated metabolite, which is only a minor
metabolite in humans [15]. Structures for these
metabolites are shown in Fig. 1. All other plasma
and urinary dapagliflozin metabolites were
formed at relatively low levels in animals and
humans and, importantly, the animals assessed
in toxicity studies formed them at sufficient
levels relative to humans to assess their safety
[14, 16] (Bristol-Myers Squibb and Astra Zeneca,
data not shown).
Dapagliflozin shows expected
pharmacodynamics (i.e., marked glucosuria)
and disease-modifying effects in a variety of
animal models of diabetes [3]. In patients with
type 2 diabetes mellitus, dapagliflozin
treatment achieves significant reductions in
HbA1c, fasting and postprandial glucose, and
body weight at the recommended human dose
of 10 mg once daily [17–27]. Both non-clinical
and clinical assessments have shown
dapagliflozin to have a highly favorable safety
profile that is consistent with its simple
mechanism of action, with no off-target effects
observed [14]. Despite a balanced overall
incidence of malignancies and unspecified
tumors between dapagliflozin and control
groups (1.5% vs. 1.4%, July 15, 2011 cutoff)
[28], regulatory concern was raised by a small
numerical imbalance in urinary bladder tumors
in the dapagliflozin global clinical program [9 in
the dapagliflozin groups vs. 1 in the placebo
groups (incidence rate of 0.15 vs. 0.03)] [29].
This imbalance was not supported by any
preclinical data suggestive of a tumor risk [30].
Thus, we hypothesized that a robust,
preclinical carcinogenic risk assessment,
including the comprehensive non-clinical
toxicity program for dapagliflozin, as well as
additional investigative studies assessing
whether dapagliflozin or its glucosuria
mechanism of action could somehow act as a
promoter or growth enhancer of bladder
tumors, would help to de-risk any clinical
tumor imbalance. The results of these studies
and the overall weight of evidence support our
conclusion that SGLT2 inhibition in general,
and dapagliflozin specifically, are not associated
with increased cancer risk.
METHODS
The definitive studies were conducted in
compliance with Good Laboratory Practice
Regulations for Nonclinical Laboratory Studies
Fig. 1 Structures of dapagliﬂozin (a), its major human
metabolite, dapagliﬂozin 3-O-glucuronide (b), and BMS-
511926, its major animal metabolite, which is O-deethy-
lated (c)
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of the United States Food and Drug
Administration (Code of Federal Regulations
Title 21, Part 58), and all in vivo studies were
approved by the Bristol-Myers Squibb
Institutional Animal Care and Use Committee
in accordance with the Association for
Assessment and Accreditation of Laboratory
Animal Care International guidelines.




formula weight *409) and D3OG were
synthesized by Bristol-Myers Squibb Company
(New Brunswick, NJ, USA). For in vitro studies,
dapagliflozin and D3OG metabolite were
dissolved in a solution of dimethyl sulfoxide.
In vivo studies were conducted with a
propylene glycol solvate of dapagliflozin
(dapagliflozin propanediol), which is the form
used in humans. The oral dosing vehicle used in
the non-clinical toxicity studies consisted of
90% polyethylene glycol (PEG-400; Spectrum
Quality Products, New Brunswick, NJ, USA) in
10% water.
In Vitro Genotoxicity Studies
In vitro genotoxicity studies were conducted in
accordance with International Conference on
Harmonization (ICH) guidelines [31].
Dapagliflozin was assessed for the potential to
induce bacterial mutation in the Ames test in
Salmonella typhimurium stains TA98, TA100,
TA1535, and TA1537 and in Escherichia coli
strain WP2 uvrA. The potential to induce
chromosome aberrations was assessed in
Chinese hamster ovary (CHO) cells. In both of
these in vitro systems, tests were performed up
to maximum concentrations established by the
ICH guidelines with and without the presence
of an aroclor-induced rat S9 metabolic
activation system (BioReliance; Rockville, MD,
USA). Appropriate positive controls were used
in each test to verify the sensitivity of the test
system.
In Vivo Rodent Cytogenetic Studies
Chromosomal Aberrations
Dapagliflozin was administered to five groups of
ten Sprague–Dawley (SD) rats per sex at doses of
0 (vehicle control), 25, 100, 150, or 200 mg/kg
per day for 1 month. All ten rats per sex were
used for toxicokinetic assessments (day 28) and
a subset of five rats per sex was used for
clastogenicity assessments in peripheral blood
cells. Cyclophosphamide served as the positive
control and was administered as a single oral
dose of 60 mg/kg to ten rats per sex
approximately 24 h prior to euthanasia.
Micronucleus Induction
Dapagliflozin was administered to groups of five
SD rats per sex at dose levels of 0 (vehicle
control), 350, 700, or 1,050 mg/kg per day
for 3 days to evaluate micronucleus induction.
The positive control group received
cyclophosphamide at 7 mg/kg per day. Bone
marrow samples were obtained approximately
24 h after administration of the last dose and
analyzed microscopically for the number of
polychromatic erythrocytes with micronuclei. A
second study was also conducted at daily doses of
0 (vehicle control), 75, 150, 200, or 250 mg/kg
per day over a 2-week period in which plasma
exposures were assessed in addition to bone
marrow micronuclei formation.
DNA Repair
The effect of dapagliflozin on unscheduled DNA
repair was evaluated in groups of ten male SD
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rats administered dapagliflozin at single oral
doses of 0 (vehicle), 175, 350, or 700 mg/kg. An
additional group of ten rats received a single
oral dose of 35 mg/kg dimethylnitrosamine as
the positive control. Animals were euthanized
2–4 h or 12–16 h after dosing. Primary
hepatocyte cultures were established from
three rats per dosing group at each time point.
Cultures were incubated with medium
supplemented with 3H-thymidine. After
approximately 4 h, cultures were processed for
autoradiographic analysis. To interpret
unscheduled DNA repair responses, the net
nuclear counts were averaged and the
mean ± standard deviation, as well as the
percent of cells in repair, was reported for each
rat evaluated. A net nuclear grain count was
calculated for each nucleus scored by
subtracting the mean cytoplasmic area count
from the nuclear area count.
Rodent Carcinogenicity Studies
Mice
CD-1 mice were obtained from Charles River
Laboratories (Raleigh, NC, USA). Dapagliflozin
was administered by oral gavage once daily for
up to 104 weeks to groups of 60 mice per sex at
doses of 0 [vehicle; PEG-400, 90% (v/v) in
distilled water], 0 (distilled water), 5, 15, or
40 mg/kg per day dapagliflozin in males and at
0 (vehicle), 0 (distilled water), 2, 10, or 20 mg/kg
per day in females. Different doses for males and
females were chosen to achieve similar drug
exposures across sexes. The doses selected for
this study were based on previous findings from
toxicokinetic and toxicologic studies. Relative
to human area under the plasma
concentration–time curve (AUC) at a dose of
10 mg, the doses in the current study were
anticipated to result in exposure (AUC)
multiples of approximately 4, 14, and 729 in
males and 11, 52, and 1059 in females. The
dose volume was 4 mL/kg per day for all dose
groups. Animals that died before the end of
treatment were necropsied for full histologic
assessment. At the end of the treatment period,
all surviving animals were euthanized and
necropsied. Groups of satellite mice (18/sex/
group) were similarly treated and euthanized for
toxicokinetic analysis during week 26. The
following parameters were evaluated: viability,
clinical observations, body weight, food
consumption, macroscopic observations,
microscopic pathology, and tumor incidence.
Pathologic evaluations were conducted and
peer reviewed by experienced veterinary
pathologists.
Rats
Harlan SD rats were obtained from Harlan
Laboratories (Indianapolis, IN, USA).
Dapagliflozin was administered by oral gavage
once daily for up to 90 (males) or 105 weeks
(females) to groups of 70 rats per sex at doses of
0 [vehicle; PEG-400, 90% (v/v) in distilled
water], 0 (distilled water), 0.5, 2, or 10 mg/kg
per day. The dose volume was 4 mL/kg per day
for all dose groups. The doses selected for this
study were based on previous findings from
toxicokinetic and toxicologic studies. Relative
to human AUC at a dose of 10 mg, the doses in
the current study were anticipated to result in
exposure (AUC) multiples of approximately 7,
25, and 1309 in males and 9, 34, and 1869 in
females. Animals that died before the end of
treatment were necropsied for full histological
assessment. Those animals that survived to the
end of the treatment period were euthanized
and necropsied. Groups of satellite rats (10/sex/
dose) were similarly treated and euthanized for
toxicokinetic analyses on day 184. The
following parameters were evaluated: viability,
clinical observations, body weight, food
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consumption, macroscopic observations,
microscopic pathology and tumor incidence.
Pathologic evaluations were conducted and




A description of the methods used to generate
and breed SGLT2-/- mice has been previously
published [32]. Briefly, founder mice were
supplied by Lexicon Pharmaceuticals, Inc. (The
Woodland, TX, USA) and back-crossed onto a
C57BL/6J strain. Parental mice were
homozygote offspring of in-house
heterozygote mating (SGLT2?/- 9 SGLT2?/-).
Homozygote mice used for this study were
offspring of next-generation in-house
homozygote mating [knockout (KO) 9 KO, or
wild-type (WT) 9 WT]. Pups were weaned at
approximately 3 weeks of age, housed in
polycarbonate boxes (one to four per box) on
Alpha-dri bedding (Shepherd Specialty Papers,
Watertown, TN, USA) with free access to water
and feed [Teklad Global 18% Protein Rodent
Diet (Harlan Laboratories)], and exposed to 12 h
of continuous light per day. Genotypes (KO or
WT) were confirmed by quantitative
polymerase chain reaction of DNA isolated
from toe snips.
The 15-month study comprised 36 (23 male,
13 female) SGLT2 KO mice and 33 (16 male, 17
female) WT mice. In-life evaluations included
daily clinical observations, periodic body
weight measurements, and a urine glucose
measurement [Diastix urine glucose test strips
(Bayer HealthCare, Tarrytown, NY, USA)] to
confirm each animal’s phenotype. Mice were
not subject to any therapeutic or pharmacologic
interventions. Animals that were found dead
prior to 15 months of age were not subjected to
necropsy. Prior to euthanasia, mice were
weighed and anaesthetized by isoflurane
inhalation. Necropsy consisted of gross
external and visceral examinations. Samples of
urinary bladder, kidneys, liver, heart, pancreas,
adrenal glands, thyroid, spleen, female
reproductive tract, male sex glands, skin,
brain, and skull were fixed in neutral buffered
formalin, routinely processed for histology, and
examined by light microscopy. Urinary bladder
evaluations were conducted and peer reviewed
by experienced veterinary pathologists.
12-Month Dog Study
Beagle dogs were obtained from Marshall Farms
(North Rose, NY, USA) and Covance Research
Products (Cumberland, VA, USA). Dapagliflozin
was administered as a solution within gelatin
capsules once daily for 48 weeks, with a 36-week
recovery period, to groups of seven per sex at
doses of 0 [vehicle; PEG-400, 90% (v/v) in
distilled water], 5, 20, or 120 mg/kg per day.
The dose volume was 4 mL/kg per day for all
dose groups. The following parameters were
evaluated: viability, clinical observations, body
weight, food consumption, macroscopic
observations, and microscopic pathology.
Pathologic evaluations were conducted and




Transcription profiling was performed on RNA
samples from a previously conducted efficacy
study in which obese male Zucker diabetic fatty
(ZDF) rats were dosed orally once daily for 1 or
5 weeks with 0 (vehicle) or 0.5 mg/kg
dapagliflozin with five animals per treatment
group for each of the time points. Liver, skeletal
muscle, kidney, and adipose tissues were
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harvested from both fasted and fed animals 48 h
after the last dose of dapagliflozin treatment
and immediately soaked in RNAlater (Qiagen,
Valencia, CA, USA) for 24 h at 4 C. The tissues
were transferred to -80 C for long-term
storage. Tissues were homogenized in Trizol
reagent (Invitrogen, Carlsbad, CA, USA) and
total RNA was isolated with RNeasy mini kit
(Qiagen) and subjected to off-column DNase I
treatment (Qiagen). All target labeling reagents
and GeneChip HT One-Cycle Target Labeling
Kits were purchased from Affymetrix (Santa
Clara, CA, USA).
Double-stranded complementary DNAs
(cDNAs) were synthesized from 1.2 lg total
RNA from each tissue sample through reverse
transcription with an oligo-dT primer
containing the T7 RNA polymerase promoter
using the cDNA Synthesis System (Affymetrix).
Biotin-labeled cRNAs were generated from the
cDNAs and were processed on a Caliper
GeneChip Array Station (Affymetrix). Labeled
cRNAs were hybridized on Affymetrix Rat
Genome HT_RG-230PM arrays and processed
according to Affymetrix’s recommendations.
Scanned images were subjected to visual
inspection and chip quality reports were
generated by Expression console (Affymetrix).
The image data were processed using the Robust
Multichip Average method to determine the
specific hybridizing signal for each probe set.
The cDNA was synthesized with a High
Capacity cDNA Reverse Transcription Kit
(Applied Biosystems; Foster City, CA, USA).
PCR primers and probe sets were obtained
from Applied Biosystems. Ingenuity Systems
Pathway Analysis (IPA) software version 9.0
(Ingenuity Systems Incorporated; Redwood
City, CA, USA) was used to annotate the
Affymetrix probesets for the genes they
represent and the functional pathways to
which they belong.
Assessment of Tumor Promotion
and Tumor Growth Enhancement
In Vitro Cell Proliferation Studies
Dapagliflozin and D3OG were evaluated for the
ability to enhance in vitro proliferation of
human bladder transitional cell carcinoma
(TCC) cell lines (T24, TCCSUP, UM-UC-3, J82,
SW780, and EJ-1). All cell lines were obtained
from American Type Culture Collection
(Manassas, VA, USA), except EJ-1, which was
obtained from Japan Health Sciences Foundation
(Osaka, Japan). These were a majority of the
human bladder TCC cell lines that could be
commercially obtained. Experiments were carried
out with low-passage cell lines that were
\6 months in culture from time of thaw of the
original cell bank stock. Three concentrations
(0.2, 2, 20 lg/mL) of each compound were
evaluated, representing approximately 1.59,
159, and 1509 the maximum observed plasma
concentration (Cmax; 136 ng/mL) for
dapagliflozin and 19, 109, and 1009 the Cmax
(196 ng/mL) for D3OG in human plasma after a
10 mg maximum recommended human dose
(MRHD) [33]. Bladder cancer cell lines were
seeded into 12 well plates at 20,000 or 40,000
cells per well in Roswell Park Memorial Institute
(RPMI) 1640 medium containing 10% fetal
bovine serum (FBS). Cells were allowed to
adhere for 24 h, at which time growth medium
was replaced with medium without FBS. After
24 h in serum-free medium, vehicle control
(medium only) or test compounds (0.2, 2,
20 lg/mL) were added in serum-free medium
and the cultures were incubated for a further
72-h period. As a positive control, some cultures
received growth medium that contained 10% FBS
after the 24-h incubation in serum free medium.
Another comparator control was maintained in
serum-containing media throughout the
duration of the experiment.
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Similarly, in a separate study, increasing
glucose concentrations were evaluated for the
ability to enhance in vitro cellular proliferation
of TCC cell lines (T24, TCCSUP, UM-UC-3, J82,
and SW780). Bladder cancer cell lines were
seeded into 12-well plates at 40,000 or 80,000
cells per well in RPMI 1640 medium containing
10% FBS and with the glucose concentration
adjusted to 11 (control), 25, 35, or 50 mM. Cells
were incubated for a 145-h period.
Cell proliferation was monitored using an
IncuCyte Live-Cell Microscope Imaging System
(Essen BioScience, Ann Arbor, MI, USA) that
resides in a standard tissue culture incubator.
Growth curves were constructed from data
points (percent confluence) acquired at 2-h
intervals over a 72-h test period for evaluation
of dapagliflozin and D3OG, and over a 145-h
test period for the evaluation of high glucose
concentrations.
In Vivo Mouse Xenograft Studies
Using a representative set of two human bladder
TCC cell lines that had already been tested
in vitro, transplantable EJ-1 or UM-UC-3 tumor
xenografts were initially established by the
inoculation of 5 9 106 cells harvested from
exponentially growing cell culture. For tumor
growth experiments, male and female athymic
nude mice (24–26 g per mouse; CrTac:NCr-
Foxn1nu; obtained from Taconic) were
implanted subcutaneously in the rear flank
with an EJ-1 or UM-UC-3 tumor fragment
(approximately 20–30 mg) using a 13-gauge
trocar. Once tumors reached approximately
100 mm3, animals were treated daily for up to
11 (for the EJ-1 tumor) or 15 (for the UM-UC-3
tumor) days with vehicle or dapagliflozin (4 and
20 mg/kg per day in males and 12 and 60 mg/kg
per day in females; differing doses between
sexes to achieve comparable exposures).
Toxicokinetics of dapagliflozin and D3OG
were evaluated following daily dosing on day
4 (UM-UC-3 mice) or day 5 (EJ-1 mice). Tumors
were measured with calipers twice weekly and
tumor volume (mm3) was estimated from the
formula tumor weight = (length 9 width2)/2,
where length is the larger and width is the
smaller of the perpendicular diameters.
Statistical Methods
Principal component analysis was performed
using Partek Discovery Suite software (Partek
Incorporated, Saint Louis, MO, USA). To
identify genes with significant expression
changes related to treatment in the
transcriptional profiling study, a two-way
analysis of variance (ANOVA) was performed
across the treatment groups. A Tukey post hoc
test was conducted to compare treatment versus
vehicle control group within the ANOVA test.
cDNA that showed a fold change of greater than
1.5 (upward or downward regulation) between
treatment and vehicle groups with a P value of
less than 0.005 were considered significantly
different in relation to treatment. Additionally,
transcriptional profiles were compared with
published literature of a proposed prognostic
genetic signature of tumor promoters [34].
Statistical significance of the in vivo effects
of dapagliflozin on tumor growth were
determined using non-parametric statistics by
Gehan’s generalized Wilcoxon test and required
a P value of less than 0.05 [35].
RESULTS
In Vitro Genotoxicity Studies
Dapagliflozin was negative in the bacterial
reverse-mutation assay in S. typhimurium and
E. coli strains at maximum concentrations
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(B5,000 lg/plate) with or without metabolic
activation. Dapagliflozin also was negative for
chromosomal aberration induction in CHO
cells in the absence of S9 stimulation. With
metabolic stimulation, 4-h exposure to
C150 lg/mL dapagliflozin increased the
incidence of structural aberrations in CHO
cells. These concentrations induced substantial
cell growth inhibition but were not excessively
cytotoxic. Importantly, these concentrations
are C735 times greater than the total Cmax
obtained in humans with the MRHD of
dapagliflozin 10 mg.
In Vivo Cytogenetics Studies in Rats
To more definitively investigate the potential
for chromosomal aberrations with
dapagliflozin, clastogenicity was evaluated in
peripheral blood cells and in bone marrow over
different durations of treatment in male and
female rats. Evaluation of peripheral blood
lymphocytes up to a maximum dose of
200 mg/kg per day of dapagliflozin for
1 month (Cmax B74 lg/mL or B5449 MRHD;
AUC B1,210 lg h/mL or B2,6029 MRHD)
showed no evidence of clastogenicity. When
tested up to the maximum tolerated dose level
for 3 days (700 mg/kg per day) or 2 weeks
(250 mg/kg per day) in bone marrow
micronucleus studies in rats, dapagliflozin was
not genotoxic up to the maximum evaluable
doses. Dapagliflozin also did not induce an
increase in unscheduled DNA synthesis in male
rats when tested to the maximum tolerated dose
(700 mg/kg) required by ICH guidelines.
The estimated or measured Cmax achieved in
the in vivo cytogenetics studies (63–74 lg/mL in
the 1-month oral in vivo/in vitro cytogenetics
assay and[100 lg/mL in the oral micronucleus
studies as extrapolated from bridging
toxicokinetics studies) approached or exceeded




Potential carcinogenicity of orally administered
dapagliflozin was assessed in CD-1 mice for a
period of up to 24 months as summarized in
Table 1. Systemic exposures in females were
higher than in males, consistent with findings in
a previous 3-month mouse study. Animals were
terminated as planned from weeks 105–106, with
survival ranging from 30%-43% in males and
from32%–47% in females after 24 months, which
was generally within expected historical control
ranges. The small reduction in the overall survival
inmalesat15and40 mg/kgperdaywas attributed
to exacerbation of mouse urologic syndrome
(MUS), a spontaneous background condition
commonly seen in untreated male CD-1 mice,
leading to urogenital obstruction and mortality
[36]. The increased incidence of the urogenital
lesions was associated with drug-related increases
in macroscopic and microscopic findings of
dilated renal pelves and urinary bladder
distention (Table 1), which suggests that
dapagliflozin caused an exacerbation of the
background lesion. The incidence and/or
severity of any background hyperplasia were
similar between dapagliflozin and control
treatment groups. Other causes of death were
distributed similarly in all dose groups and/or
were not dose related.
Dapagliflozin was not carcinogenic in CD-1
mice when administered by oral gavage for up
to 24 months at doses B40 mg/kg per day [AUC
from time zero to 8 h (AUC0–8h) = 33.5 lg h/
mL; 729 AUC0–8h MRHD] in males or at doses
B20 mg/kg per day [AUC from time zero to 24 h
(AUC0–24h) = 48.6 lg h/mL; 1059 AUC0–24h
MRHD] in females. Neoplasms of the
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lymphoreticular system, uterus and cervix,
lung, and liver were observed in the water and
vehicle control groups. Dapagliflozin did not
increase the incidence of these background
tumors or shorten the time to onset.
Importantly, there were no indications of any
tumors in the urogenital tract or urinary bladder
despite some background hyperplastic effects in
the bladder of male mice. Dapagliflozin did not
increase urinary bladder hyperplasia over that
observed in control male mice (Fig. 2).
Moreover, no difference was observed in the
kidney between control and dapagliflozin-
treated mice, except for the aforementioned
increased incidence of dilated renal pelves.
SD Rats
Similar carcinogenicity studies were conducted
in SD rats for a period of up to 24 months as
summarized in Table 2. Female rats were
Fig. 2 Bladder tissue histology in mice treated with vehicle
control or dapagliﬂozin 40 mg/kg per day for[20 months
and in rats treated with control or dapagliﬂozin 10 mg/kg
per day for 90 weeks. a Bladder displaying incidental
hyperplasia in dapagliﬂozin-treated (left) and control (right)
male mice. In both cases, there is moderate hyperplasia of
the transitional cell urothelial lining of the urinary bladder,
characterized by thickening of the urothelium with an
increased number of uniform cells retaining the differen-
tiated and relatively organized character of regular
epithelium, with no cellular atypia. The apparent variation
in thickness is partially due to folding and/or tangential
sectioning. The incidental hyperplasia is secondary to
inﬂammation/infection, often related to mouse urologic
syndrome. b Urinary bladder in dapagliﬂozin-treated (left)
and control (right) male rats. In both cases, the transitional
cell urothelial lining of the urinary bladder appears normal
and relatively thin. 9100 magniﬁcation
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terminated as planned at weeks 105–106. Due to
declining survival in males in the two control
groups and the 10 mg/kg per day group, males
in all groups were terminated at weeks 89–91 to
ensure sufficient numbers of rats for statistical
analysis. In males, the most common cause of
death was chronic progressive nephropathy
(CPN), a common background finding in SD
rats [37]. The higher incidence of death at
10 mg/kg per day in males was attributable to
a dapagliflozin-related increase in severity of
this commonly observed background condition
(Fig. 3).
Dapagliflozin was not carcinogenic in rats at
doses up to 10 mg/kg per day. There was a low
incidence of pituitary tumors in the male rats,
but the incidence of these tumors did not
increase in the dapagliflozin groups. In female
rats, the most common causes of death were
benign and malignant mammary and pituitary
tumors, but there was no dapagliflozin-related
increase in the incidences or in the time to
Fig. 3 Kidney tissue histology in mice treated with vehicle
control or dapagliﬂozin 40 mg/kg per day for[20 months
and kidney pathology in rats treated with control or
dapagliﬂozin 10 mg/kg per day for 90 weeks. a Kidney in
dapagliﬂozin-treated (left) male mice and control (right). In
both cases, the kidney cortex appears similar and shows
normal glomeruli and renal cortical tubules. b Chronic
progressive nephropathy (CPN) in control (left, moderate)
and dapagliﬂozin-treated (right, severe) rats. The CPN is
characterized by multifocal dilated tubules often ﬁlled with
proteinaceous ﬂuid, tubules with cytoplasmic basophilia
and focally thickened tubular basement membranes, and
foci of increased mononuclear cell inﬁltrates in the
interstitium. There was exacerbation of CPN (increased
severity) in the dapagliﬂozin-treated male rats (i.e., higher
incidence of severe CPN in the dapagliﬂozin-treated males
vs. controls). 9100 magniﬁcation
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onset of these tumors. Importantly, there were
no indications of any dapagliflozin-related
tumors or preneoplastic lesions in the urinary
bladder (Fig. 2) in rats. There were also no
dapagliflozin-related neoplasms affecting the
renal tubules, adrenal gland, or testicular
Leydig cells as has been reported by the US
Food and Drug Administration for
canagliflozin [38]. In males only, there were
microscopic changes in the kidney, which
included exacerbation in severity of CPN and
increased incidence and severity of minimal to
marked atypical hyperplasia of renal cortical
tubules.
Additional Supportive Animal Studies
Dog Toxicology Studies
Dogs have previously been reported to be
uniquely susceptible to urinary bladder
tumorigenesis [39]. Thus, dogs treated with
dapagliflozin for 1 year at supratherapeutic
doses and exposures [3,3009 the human
clinical exposure may be particularly relevant
to a potential concern regarding urinary bladder
tumors. Despite marked pharmacologic
increases in urinary glucose excretion
(8,711–32,200 mg per day) compared with
control animals (5–13 mg per day), evaluation
of the urinary bladder of dogs treated with




Our previous report indicated that systemic
(i.e., plasma AUCs) exposures to dapagliflozin
and its primary human metabolite, D3OG, in
animal toxicity and carcinogenicity studies
were at least equal to and often far exceeded
human exposures at the MRHD [14].
Subsequently, we used bridging studies to
extrapolate urinary exposures to these drug
analytes (data not shown). Similar to plasma
exposures, extrapolated urinary concentrations
of dapagliflozin in mice, rats, and dogs were
[7009 relative to humans, and extrapolated
urinary concentrations of the D3OG metabolite
were 1–159 in rodents and 309 in dogs relative
to humans.
SGLT22/2 Mice
SGLT2 KO mice, not receiving any treatment,
were used to evaluate the potential carcinogenic
risk of inhibiting SGLT2, particularly in the
urogenital tract chronically exposed to
glucosuria and diuresis. At 15 months, 86% of
the KO animals and 85% of the WT animals
survived. WT animals were negative for
glucosuria, and mean body weight was similar
in the KO and WT mice at 15 months. As
expected, KO mice exhibited substantial
glucosuria (2,000 mg/dL), but there was
otherwise no indication of other phenotypic
differences in SGLT2 KO mice compared with
WT mice, including no evidence of any renal
dysfunction in SGLT2 KO mice.
Microscopic evaluation of the urinary
bladder, kidneys, liver, heart, pancreas,
adrenal glands, thyroids, spleen, female
reproductive tract, male sex glands, skin,
brain, and skull did not reveal any adverse
effect attributable to SGLT2 gene deletion. Of
particular note, no hyperplasia or neoplasia
was observed in the urinary bladder mucosa
(Fig. 4), urogenital tract, or kidneys. One
SGLT2 KO male had polycystic kidney
disease, a known spontaneous background
condition in C57BL/6J mice [40], and,
therefore, not attributable to SGLT2 gene
deletion. Histopathology of this animal was
consistent with this condition.
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Assessment of Tumor Promotion
and Tumor Growth Enhancement
Transcriptional Profiling
In an attempt to evaluate whether dapagliflozin
was associated with any changes in the
transcriptional profile of insulin-responsive and
renal tissues and also any risk factors for tumor
promotion, transcriptional profiling was
performed in several representative tissues
(although not including the bladder) following
5 weeks of dapagliflozin treatment and in the
context of a diabetic state in rats. Principal
Component Analysis of the entire transcription
profiling data set showed that animals of each
treatment group clustered together, with clear
separation between fasted and fed groups and
between dapagliflozin and vehicle treatment
groups. Dapagliflozin produced slightly more
gene expression changes in the male ZDF rats
compared with vehicle-treated controls, but less
than 1% of the probe sets showed significant
changes. Transcriptional changes were primarily
observed in the liver and related to glucose
metabolism, while no major changes were
observed in kidney, skeletal muscle, or adipose
tissue. Importantly, very few genes involved in
cell cycling, cell regulation, or cell contact were
affected and none of the gene expression changes
that have been reported to be prognostic
indicators of tumor promoters [34, 41] were
observed to occur with dapagliflozin treatment
in the multiple tissues that were profiled and in
the context of the diabetic disease state (see
Supplemental Tables S1 and S2 in the Electronic
Supplementary Material).
In Vitro Cell Proliferation Studies
As expected, all six human bladder TCC cell
lines showed a robust proliferative response to
serum added to the culture medium. In
contrast, neither dapagliflozin nor D3OG
(Supplemental Figures S1 and S2 in the
Electronic Supplementary Material) at
concentrations up to 20 lg/mL (and C1009
human plasma Cmax and [209 human urinary
concentrations) stimulated cell proliferation
relative to cells that were kept in serum-free
medium throughout the 72-h period.
In the assessment of increased glucose
concentrations (Supplemental Figure S3 in the
Electronic Supplementary Material), increasing
concentrations of glucose did not enhance TCC
growth. In fact, while concentration of 25 mM
did not substantially alter the growth of the T24
or the SW780 cell lines, it reduced the growth of
Fig. 4 Bladder tissue histology in wild-type (left) and SGLT-/- (right) mice shows normal microscopic morphology for
both. 9200 magniﬁcation
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the J82, TCCSUP, and UM-UC-3 lines by 37%,
42%, and 73%, respectively. The growth of all cell
lines was completely inhibited at both 35 mM
and 50 mM glucose in the media, except for the
T24 cell line, which demonstrated some growth
(although reduced by 83%) in media containing
35 mM glucose, in comparison to the normal
urinary glucose range of 0–0.8 mM in individuals
without diabetes [42].
Assessment of Tumor Growth Enhancement
In Vivo
Dapagliflozin (Fig. 5) at exposures up to 759
human clinical exposures also had no effect on
Fig. 5 Logarithmic plot of growth of human urinary
bladder transitional cell carcinoma cell line tumors in
xenograft mouse models administered vehicle (control),
dapagliﬂozin 4 mg/kg or dapagliﬂozin 20 mg/kg for 14 days
in mice injected with the EJ-1 cell line and for 11 days in
mice injected with the UM-UC-3 cell line. Tumor growth
was similar in dapagliﬂozin-treated mice and controls.
DAPA dapagliﬂozin
88 Diabetes Ther (2014) 5:73–96
the growth of both the EJ-1 and UM-UC-3
tumor xenografts in either male or female nude
mice. Dapagliflozin was well tolerated,
producing no effect on the body weight of
treated animals.
DISCUSSION
This article provides a comprehensive
preclinical evaluation of the potential
carcinogenic risk for selective SGLT2
inhibition and specifically for the first drug in
this new therapeutic class to reach the
marketplace, dapagliflozin. While the authors
acknowledge that these data cannot definitively
prove the absence of any carcinogenic risk, they
provide very strong weight of evidence that
selective SGLT2 inhibition in general, and
dapagliflozin specifically, do not present a risk
for initiating, promoting, or enhancing
malignancies.
Structure–activity analyses, a variety of
genotoxicity assessments, and 2-year rodent
carcinogenicity assays with dapagliflozin at
exposures that far exceeded clinical relevance,
were all negative, indicating that neither
dapagliflozin nor its metabolites are tumor-
initiating carcinogens. There was also no
decrease in time to onset or overall increase in
the incidence of common background tumor
types (e.g., mammary tumors in rats) suggesting
that dapagliflozin does not promote tumor
growth. Furthermore, no evidence was
observed of dapagliflozin-related proliferative
or hyperplastic effects (i.e., neoplastic
precursors) in the urinary bladder in the
rodent carcinogenicity studies at [1009
MRHD exposures. Although no neoplasms
were observed in the kidney, there was an
increase in the incidence and severity of
atypical hyperplasia in the cortical tubules of
male rats. As atypical hyperplasia of renal
tubules is a common sequel to advanced CPN,
the increased atypical hyperplasia was
considered a direct result of the increased
severity of CPN in these animals. While CPN-
associated hyperplastic renal tubular epithelium
is a potential precursor of renal tubular
epithelial tumors in rats, such tumors were not
observed in the current study and they are not
considered a predictor of renal tumors in
humans [43]. Of note, since the SGLT2
inhibitor phlorizin is pharmacologically active
in the renal cortex of rats with experimental
diabetes, it is also likely that dapagliflozin
retains its pharmacological activity in the
hyperplastic renal tubular epithelium of rats
with CPN [44].
The absence of any carcinogenicity risk
signals in the 2-year rodent bioassays is
noteworthy as the studies presented herein
assessed dapagliflozin effects at exposures
[1009 MRHD. Moreover, the rodent
carcinogenicity assays were not confounded by
the presence of any hormonal perturbation or
immunotoxicologic effects, which are primarily
responsible for the relatively small number of
false negatives that have been reported [45].
Dapagliflozin did not bind to hormone
receptors in secondary pharmacology screens
nor did it induce changes in repeat-dose rat
toxicity studies that would be consistent with
hormonal perturbation (e.g., no microscopic
changes in any sex organs, and no changes in
onset of puberty, estrous cycling, or fertility)
[14]. There was also no evidence of
immunotoxicologic effects in repeat-dose
toxicity studies conducted with dapagliflozin
(e.g., no changes in lymphoid tissue or
hematology parameters).
The lack of carcinogenicity findings is
further supported by chronic toxicity studies
conducted in rats and dogs that similarly
showed no carcinogenicity [14]. The lack of
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dapagliflozin-related proliferative/hyperplastic
changes in the 12-month toxicity study
conducted in dogs at [3,0009 MRHD
exposures is noteworthy as dogs are
particularly sensitive to bladder carcinogenesis
[39]. Although the effects observed in the
rodent and dog bioassays are not a guaranteed
predictor of a lack of a cancer risk for humans,
the complete absence of any effects or risk
factors in these and other assays provides strong
evidence for the absence of a true cancer risk of
dapagliflozin to humans.
The observed reduction in overall survival in
male mice receiving 15 and 40 mg/kg per day
dapagliflozin is most likely related to the
diuretic effects of dapagliflozin in mice and
not to any potential increased risk for cancer.
The early deaths observed in these animals were
attributable to exacerbation of MUS, a
spontaneous, mouse-specific background
condition commonly seen in untreated male
CD-1 mice that leads to urogenital obstruction
and mortality [36]. MUS was observed in CD-1
mice but not in SGLT2-/- mice likely due to
differences among strain [46–48], age, and
housing conditions. For example, CD-1 mice
are inherently more susceptible to MUS, were
older than the SGLT2-/- mice, and were housed
in wire-bottom cages, which have been shown
to exacerbate incidence and severity of MUS
[46]. Similarly, the increased mortality in male
rats observed with dapagliflozin was due to an
exacerbation of CPN. CPN is also a common
spontaneous lesion that has no counterpart in
humans and has recently been discussed as
being of little relevance to human risk
assessment [49]. The non-neoplastic findings
in mice and rats were not associated with other
microscopic changes and were likely adaptive
responses to increased urine volume secondary
to osmotic diuresis due to increases in urinary
glucose excretion. Similar changes in the kidney
and urinary bladder of male mice and rats have
also been reported in 24-month carcinogenicity
studies with the diuretic furosemide [50], which
were also not associated with any tumorigenic
risks. Given that both MUS and rat CPN are
species specific and without a counterpart in
humans, these data showed no increased risk
that would be relevant to humans.
The entirety of the preclinical toxicology
study program was also noteworthy in terms of
appropriateness for testing of on- and off-target
effects from dapagliflozin or its metabolites.
Dapagliflozin is pharmacologically active in all
of the preclinical animal species used and the
exposures in animals were in such excess of
human exposures that the potential for off-
target effects could be reliably tested. Moreover,
the metabolic profile across species is
qualitatively similar, with no unique human
metabolites, and, when one considers the high
doses tested in toxicology studies, is
quantitatively suitable for safety evaluation of
all metabolites.
The absence of any non-clinical evidence for
tumor risk is consistent with results from the
clinical program, in which the dapagliflozin and
control groups were balanced for the overall
occurrence of malignant and unspecified
tumors [28, 29]. As would be expected for a
drug that does not cause malignancy, the
incidence rate for tumors was lower in the
comparator group in some organ systems and
lower in the dapagliflozin group in others,
leading to the overall balance in total
malignancies. However, there was a numerical
imbalance in bladder cancer cases [9 of 5,501
patients (0.16%) treated with dapagliflozin and
1 of 3,184 patients (0.03%) treated with
placebo/comparator in analysis performed
with a July 15, 2011, cutoff] [29]. It should be
noted that although the number of bladder
cancer cases was small, and a number of
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patients in the clinical trial had preexisting
hematuria (a known risk factor for bladder
cancer), there was concern that dapagliflozin
and/or its associated glucosuric effect could
somehow act to promote or enhance
preexisting neoplastic lesions or tumors.
However, the non-clinical program
demonstrated that dapagliflozin does not
exhibit any mechanistic characteristics of a
classic tumor-promoting agent. Specifically, it
did not lead to formation of crystalline solids or
pH changes, was not irritating, did not
cause direct cytotoxicity or inflammatory
changes, and was not associated with
immunosuppressive or hormonally disruptive
properties. Additional studies were conducted
to further evaluate tumor-initiating or
-promoting potential in the context of
diabetes and specific to the bladder.
To assess potential carcinogenic
contributions of drug–disease interaction, an
analysis of a highly predictive genetic tumor
promoter signature was performed in liver,
skeletal muscle, kidney, and adipose tissue
from the ZDF rat model of diabetes. This
analysis focused on a battery of genetic
markers validated by Maeshima et al. [34, 41]
to be highly correlated with in vivo tumor-
promoting activities and rodent carcinogenicity
and that showed 96% accuracy, sensitivity, and
specificity for positive results in a two-stage cell
transformation assay in Balb/c 3T3 cells.
Dapagliflozin treatment did not induce
transcriptional changes in the selected panel
of tissues that would be characteristic of tumor
promoters. Although the bladder was not
specifically sampled (and histologic evaluation
was not performed in this short duration study),
the absence of any transcriptional changes
suggestive of a tumor promoter in other
tissues and the results of the additional
carcinogenicity and genotoxicity assessments
support the overall conclusion that
dapagliflozin does not have a tumor promoter
effect.
Consistent with the literature, the current
study also found no evidence that elevated
glucose levels stimulated cell proliferation as
characterized by hyperplastic changes that are
requisite for tumor promotion [51]. No
evidence of dapagliflozin-related proliferative
or hyperplastic effects in the bladder was
observed throughout the toxicology program,
in which glucosuria was a consistent finding
[14]. High levels of urinary glucose on the order
of 200 mM in the 2-year rodent carcinogenicity
studies and up to 400–500 mM in the chronic
toxicology studies, which correspond well to
those observed in human subjects (mean of
166 mM at a 10 mg dose) [21], did not lead to
bladder tumor development, even in male mice
in which background bladder hyperplasia was
observed. Additionally, an analysis of
15-month-old SGLT2-/- mice that had
experienced a lifetime of glucosuria failed to
reveal evidence of proliferative, hyperplastic, or
preneoplastic type changes. If glucosuria
stimulated or promoted tumor proliferation,
these environments would likely have led to
progression from hyperplasia to preneoplastic
lesions.
Having found no evidence that dapagliflozin
or glucosuria exert hyperplastic or tumorogenic
effects, we explored the possibility that glucose
itself, dapagliflozin, or its primary human
metabolite could enhance or accelerate growth
of bladder tumor cells. We used an
experimental strategy similar to the one that
was used to analyze the antithrombotic drug
prasugrel [52]. Prasugrel also led to numerical
imbalances in specific tumor types during phase
3 clinical trials despite the absence of any other
preclinical cancer signals associated with the
drug. In the current study, neither glucose,
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dapagliflozin, nor its primary human
metabolite enhanced urinary bladder TCC
tumor cell growth in vitro or heterotopically
in a mouse xenograft model system at exposures
up to 759 and 0.99 (dapagliflozin and its
primary metabolite, respectively) human
clinical exposures.
The findings of these studies, showing no
bladder cancer signal, are further supported
when placed in the context of what is known
regarding SGLT2. SGLT2 is expressed almost
entirely in the kidney, not the bladder;
therefore any on-target effects would be
expected to occur in the kidney [8, 9].
Moreover, dapagliflozin is highly selective for
SGLT2, which makes off-target effects unlikely
[6, 14]. To date, there is no published report of
cancer risk associated with selective SGLT2
inhibition. To the contrary, some published
data suggest that inhibition of SGLT2 may
actually decrease growth in tumor cells
expressing this transporter by inhibiting
glucose uptake into the malignant cells [53,
54]. In vitro data from this study have shown
that supraphysiologic urinary glucose
concentrations above 20 mM, which is still
well below the levels caused by dapagliflozin
in the clinic (166 mM) and in animal studies
(up to 400–500 mM) [14, 21], actually inhibited
tumor cell growth of a variety of human bladder
TCC tumor cell lines.
Recently, carcinogenicity results for
canagliflozin, an SGLT2 inhibitor that,
compared with dapagliflozin, is less selective
for SGLT2 than for SGLT1 (canagliflozin, 2009;
dapagliflozin, 1,2009) [55], were publically
disclosed [38]. Canagliflozin did not increase
the incidence of neoplasms or preneoplastic
lesions in CD-1 mice in a 2-year carcinogenicity
study at exposures 149 clinical exposures [38].
In rats, canagliflozin increased the incidence of
neoplasms of the renal tubules (C129), adrenals
(C129), and testicular Leydig cells of SD rats
(C19). These events have been hypothesized to
be related to carbohydrate malabsorption and
calcium imbalance due to SGLT1 inhibition,
which may explain why similar tumors were
not observed with dapagliflozin. In neither
rodent species was there any evidence of an
increased risk of bladder tumors. Publically
disclosed clinical results for canagliflozin also
did not suggest any malignancy signal (with
8,000 person-years exposure), further
supporting the safety of SGLT2 inhibition in
humans [38].
CONCLUSION
The studies presented here were undertaken
because it is well recognized that even the most
extensive clinical development programs can at
best only provide safety screening signals
related to human malignancies, especially for
risks involving specific cancer types. Using a
multitude of different approaches and at high
multiples of human exposures, this
comprehensive non-clinical safety program
provided a substantial body of evidence
suggesting no indication of tumor initiation or
promotion or enhancement of tumor
progression associated with selective SGLT2
inhibition in general or with dapagliflozin
specifically. Therefore, these results support
the finding of no overall imbalance in
malignancy observed in clinical trials and add
to the weight of evidence regarding the overall
safety of dapagliflozin in humans.
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